PE20221836A1 - Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 - Google Patents
Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5Info
- Publication number
- PE20221836A1 PE20221836A1 PE2022002114A PE2022002114A PE20221836A1 PE 20221836 A1 PE20221836 A1 PE 20221836A1 PE 2022002114 A PE2022002114 A PE 2022002114A PE 2022002114 A PE2022002114 A PE 2022002114A PE 20221836 A1 PE20221836 A1 PE 20221836A1
- Authority
- PE
- Peru
- Prior art keywords
- receptor
- alkyl
- gaba
- alpha5
- compounds
- Prior art date
Links
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 title 1
- DVXYZLCJSYRIPC-UHFFFAOYSA-N pyrido[3,4-c]pyridazine Chemical class C1=NN=C2C=NC=CC2=C1 DVXYZLCJSYRIPC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 2
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000029560 autism spectrum disease Diseases 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- -1 -tert-butyl carboxylate Chemical class 0.000 abstract 1
- QNKIFGXUKZAWLR-UHFFFAOYSA-N CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O Chemical compound CC1=C(C(=NO1)C=1C=NC(=CC=1)C)COC=1C=C2CCN(CC2=CN=1)C(C)=O QNKIFGXUKZAWLR-UHFFFAOYSA-N 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000113 | 2020-03-26 | ||
| PCT/IB2021/052486 WO2021191838A1 (en) | 2020-03-26 | 2021-03-25 | NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221836A1 true PE20221836A1 (es) | 2022-11-29 |
Family
ID=89666363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002114A PE20221836A1 (es) | 2020-03-26 | 2021-03-25 | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa 5 |
Country Status (22)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
| HU231691B1 (hu) * | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116854685A (zh) * | 2022-03-28 | 2023-10-10 | 上海赛默罗生物科技有限公司 | 异噁唑-稠环类衍生物、药物组合物和用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1237793B (it) | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| WO1998050385A1 (en) | 1997-05-08 | 1998-11-12 | Merck Sharp & Dohme Limited | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS |
| GB9813576D0 (en) | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB0017518D0 (en) | 2000-07-17 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| US7595395B2 (en) | 2005-05-16 | 2009-09-29 | Wisys Technology Foundation | Gabaergic agents to treat memory deficits |
| CN101277952B (zh) | 2005-10-11 | 2011-09-28 | 弗·哈夫曼-拉罗切有限公司 | 异*唑衍生物 |
| DE602006014185D1 (de) | 2005-11-09 | 2010-06-17 | Hoffmann La Roche | 3-arylisoxazol-4-carbonylbenzofuranderivative |
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| ES2340221T3 (es) | 2006-05-24 | 2010-05-31 | Eli Lilly And Company | Compuestos y procedimientos para modular fxr. |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| BRPI0812521A2 (pt) | 2007-06-13 | 2015-06-23 | Glaxosmithkline Llc | Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto |
| US7618973B2 (en) | 2007-12-04 | 2009-11-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| JP5301557B2 (ja) | 2007-12-04 | 2013-09-25 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| KR101354416B1 (ko) | 2009-05-07 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체 |
| CN103189062B (zh) | 2010-11-05 | 2016-03-23 | 霍夫曼-拉罗奇有限公司 | 活性药物化合物用于治疗中枢神经系统病症的用途 |
| RU2582337C2 (ru) | 2010-11-09 | 2016-04-27 | Ф.Хоффманн-Ля Рош Аг | Производные триазола в качестве лигандов рецепторов гамк |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| KR20140014205A (ko) * | 2011-03-04 | 2014-02-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Mst1 키나제 억제제 및 그의 사용 방법 |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US8604062B2 (en) | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
| EP2885290B1 (en) | 2012-06-26 | 2017-10-18 | Saniona A/S | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| MX357504B (es) * | 2012-06-26 | 2018-07-12 | Saniona Aps | Derivado de feniltriazol y su uso para modular complejo del receptor gabaa. |
| WO2014001278A1 (en) * | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN102924452B (zh) * | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| EP4032889B1 (en) | 2013-12-20 | 2026-05-06 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US9296747B1 (en) * | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| CA2990564A1 (en) | 2015-06-22 | 2016-12-29 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| JP2018525429A (ja) | 2015-08-28 | 2018-09-06 | アッヴィ・インコーポレイテッド | S1p調節剤としての縮合複素環化合物 |
| CN108602811B (zh) | 2016-02-01 | 2021-11-16 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| EP4129297A1 (en) | 2016-03-18 | 2023-02-08 | UWM Research Foundation, Inc. | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists |
| MA48594B1 (fr) | 2016-12-08 | 2022-05-31 | Hoffmann La Roche | Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a |
| US20200268728A1 (en) * | 2016-12-20 | 2020-08-27 | Sumitomo Dainippon Pharma Co., Ltd. | Drug targeting cancer stem cell |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| MX2020005447A (es) | 2017-11-27 | 2020-12-03 | Dart Neuroscience Llc | Compuestos de furanopirimidina sustituida como inhibidores de pde1. |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素V1a受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| AU2019286312B2 (en) | 2018-06-13 | 2023-08-17 | F. Hoffmann-La Roche Ag | New isoxazolyl ether derivatives as GABA A alpha5 PAM |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| TWI716107B (zh) | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| US12649738B2 (en) | 2020-03-26 | 2026-06-09 | Richter Gedeon Nyrt. | 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators |
-
2021
- 2021-03-11 TW TW110108696A patent/TWI901650B/zh active
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 GE GEAP202116066A patent/GEP20257761B/en unknown
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en not_active Ceased
- 2021-03-25 JP JP2022557102A patent/JP7805946B2/ja active Active
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 AU AU2021244926A patent/AU2021244926B2/en active Active
- 2021-03-25 GE GEAP202416066A patent/GEAP202416066A/en unknown
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 US US17/907,174 patent/US12637455B2/en active Active
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko active Pending
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 PH PH1/2022/552340A patent/PH12022552340A1/en unknown
- 2021-03-25 CU CU2022000058A patent/CU24714B1/es unknown
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-13 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2022014877A2 (es) | 2022-10-31 |
| GEP20257761B (en) | 2025-04-10 |
| BR112022019128A2 (pt) | 2022-11-08 |
| IL296716A (en) | 2022-11-01 |
| MX2022011933A (es) | 2022-10-20 |
| JOP20220219A1 (ar) | 2022-09-13 |
| PH12022552340A1 (en) | 2023-11-29 |
| KR20220160061A (ko) | 2022-12-05 |
| CA3171441A1 (en) | 2021-09-30 |
| JP2023520647A (ja) | 2023-05-18 |
| WO2021191838A1 (en) | 2021-09-30 |
| EP4126859A1 (en) | 2023-02-08 |
| AU2021244926B2 (en) | 2026-06-25 |
| US20240067637A1 (en) | 2024-02-29 |
| TWI901650B (zh) | 2025-10-21 |
| CU20220058A7 (es) | 2023-05-11 |
| JP7805946B2 (ja) | 2026-01-26 |
| AR121666A1 (es) | 2022-06-29 |
| ZA202211414B (en) | 2023-06-28 |
| CU24714B1 (es) | 2024-07-10 |
| US12637455B2 (en) | 2026-05-26 |
| AU2021244926A1 (en) | 2022-11-03 |
| CL2022002568A1 (es) | 2023-03-24 |
| TW202202495A (zh) | 2022-01-16 |
| GEAP202416066A (en) | 2024-12-10 |
| CN115348962A (zh) | 2022-11-15 |
| ECSP22082367A (es) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12459958B2 (en) | Tricyclic compounds as HPK1 inhibitor and the use thereof | |
| AU2011258217B2 (en) | Heteroaryl compounds and methods of use thereof | |
| US9695171B2 (en) | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors | |
| CA2878054C (en) | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors | |
| US20170073343A1 (en) | Novel Imidazo[4,5-c]Quinoline And Imidazo[4,5-c][1,5]Naphthyridine Derivatives As LRRK2 Inhibitors | |
| WO2013042137A1 (en) | Bicyclic heterocycles as irak4 inhibitors | |
| JP6515175B2 (ja) | 芳香族ヘテロ環誘導体及びその医薬的適用 | |
| WO2015090235A1 (en) | Substituted piperazine compounds and methods of use thereof | |
| JP2020505397A (ja) | Lrrk2キナーゼ活性を阻害するための化合物 | |
| AU2017213498A1 (en) | Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system | |
| US20140329820A1 (en) | Triazine Derivatives | |
| JP2019519507A (ja) | 神経障害の治療法 | |
| JP6345651B2 (ja) | ヘテロアリール化合物及びその使用方法 | |
| CN104496987B (zh) | 取代杂环类化合物及其在药物上的应用 | |
| OA22045A (en) | APOL1 inhibitors and methods of use. | |
| TW202402751A (zh) | 鐵死亡調節物、製劑及其使用 |